共 43 条
- [31] A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Fujii, TakeoMasuda, HirokoCheng, Yee ChungYang, FeiSahin, Aysegul A.Naoi, YasutoMatsunaga, YukiRaghavendra, Akshara SingareekaSinha, Arup KumarFernandez, Jose R. EspinosaJames, AnjaliYamagishi, KeisukeMatsushima, TomokoTripathy, DebuTada, SachiyoJackson, Rubie S.Noguchi, ShinzaburoNakamura, SeigoAcoba, Jared DavidUeno, Naoto T.
- [32] Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26CANCER MEDICINE, 2019, 8 (09): : 4176 - 4188Turner, Bradley M.Gimenez-Sanders, Mary AnnSoukiazian, ArmenBreaux, Andrea C.Skinner, KristinShayne, MichelleSoukiazian, NyrieLing, MarilynHicks, David G.
- [33] Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancerCANCER RESEARCH, 2017, 77Schroeder, B. E.Zhang, Y.Stal, O.Fornander, T.Brufsky, A.Sgroi, D. C.Schnabel, C. A.
- [34] Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC StudyCANCER RESEARCH, 2012, 72Sgroi, D. C.Sestak, I.Cuzick, J.Zhang, Y.Schnabel, C. A.Erlander, M. G.Goss, P. E.Dowsett, M.
- [35] Comparison of predicted benefit using RS clin versus observed benefit in a US registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Walden, Christopher DavidMosiman, SamuelBorgert, Andrew J.Parsons, Benjamin Marshall
- [36] Differential patient stratification by the breast cancer index Hox613/1L17BR ratio vs recurrence score (RS) plus quantitative ER expression in hormone receptor positive, node negative breast cancerCANCER RESEARCH, 2016, 76Naughton, M. J.Schroeder, B. E.Operana, T. N.Zhang, Y.Schnabel, C. A.
- [37] Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approachJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Tang, G.Cuzick, J.Wale, C.Costantino, J. P.Crager, M.Shak, S.Wolmark, N.Dowsett, M.Forbes, J. F.
- [38] Validation of the prognosis of patients with ER-positive, HER2-negative and node-negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi-institutional registry studyONCOLOGY LETTERS, 2023, 25 (05)Naoi, YasutoTsunashima, RyoShimazu, KenzoOikawa, MasahiroImanishi, SeiichiKoyama, HiroshiKamada, YoshihikoIshihara, KazuhiroSuzuki, MasahikoOsako, TomoKinoshita, TakayukiSuto, AkihikoNakamura, SeigoTsuda, HitoshiNoguchi, Shinzaburo
- [39] Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence ScoresRADIOLOGY, 2016, 280 (02) : 370 - 378Dialani, VandanaGaur, ShantanuMehta, Tejas S.Venkataraman, ShambhaviFein-Zachary, ValeriePhillips, JordanaBrook, AlexanderSlanetz, Priscilla J.
- [40] The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® TestingCANCERS, 2023, 15 (03)Turner, Bradley M. M.Finkelman, Brian S. S.Hicks, David G. G.Numbereye, NumbereMoisini, IoanaDhakal, AjaySkinner, KristinSanders, Mary Ann G.Wang, XiShayne, MichelleSchiffhauer, LindaKaterji, HaniZhang, Huina